CLIFTON, N.J. (PRWEB) May 03, 2021
Integrated Medical Communications is proud to announce the inaugural issue of a magazine focused on the most up-to-date news in the world of genitourinary cancer.
GU Oncology Now is a new journal that will publish nine issues in 2021. The first issue highlights new therapeutics in advanced prostate cancer, and a future issue will discuss precision medicine in prostate cancer. Volume two will share summaries of research presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium. Future issues will focus on additional conferences, including ASCO as well as the Society of Nuclear Medicine & Molecular Imaging (SNMMI), American Urological Association (AUA), European Society for Medical Oncology (ESMO), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO).
GU Oncology Now will have a circulation of over 14,000, with recipients including medical oncologists, urologists, radiation oncologists, and nuclear medical radiologists who will benefit from the latest news surrounding genitourinary cancer.
“This is a very exciting time in the world of oncology, and in genitourinary cancer in particular,” said publisher Joe Palumbo, CEO of Integrated Medical Communications. “As advances in treatments and technologies continue, we are looking forward to keeping oncologists, radiologists, and everyone else in the field abreast of the latest news in the space. It’s our intention to provide knowledge, interviews with experts, results of ongoing clinical trials, conference summaries, and information that will be useful to your clinical practice. Our vision is to create a high-quality publication that is relevant, challenging, and thought-provoking.”
In the very first issue, GU Oncology Now offers interviews with two widely recognized experts in the field. Andrei Iagaru, MD, Professor of Radiology – Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford Health Care, discusses the latest updates in prostate cancer imaging using positron emission tomography (PET). And Scott T. Tagawa, MD, Professor of Medicine and Urology at Weill Cornell Medicine, and Attending Physician at New York-Presbyterian – Weill Cornell Medical Center, explains the benefits and roadblocks of prostate-specific membrane antigen (PSMA)-targeting in prostate cancer treatment, as well as upcoming therapies in the pipeline for prostate cancer treatment.
About Integrated Medical Communications
Integrated Medical Communications (IMC) is a recently founded medical publishing company aimed at providing the latest in healthcare news and published literature to healthcare professional across multiple specialties. IMC promotes excellence through providing news that is fair, balanced, and accurate. IMC collaborates with societies, organizations, thought leaders and experts to develop high level content in both digital and print platforms. To learn more, visit: https://www.integratedmedicalcommunications.com/